RxDoctor Payments DataLook up a doctor →

Scott Schaeffer, MD

General Practice · Wilmington, DENPI 1649242801

Payments from drug & device makers

$15,704in general payments, 2019–2025

Across 958 payments — averaging $16.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Amgen$1K
  • AstraZeneca$1K
  • Lilly USA, LLC$1K
  • Novo Nordisk$951
  • Pfizer$855
  • plus $8K from 54 others

What the payments were for

  • Consulting fees$250%
  • Food & beverage$15,57499%
  • Education$1061%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)124$1,993
Amgen(2 entities)96$1,466
AstraZeneca66$1,202
Lilly USA, LLC69$1,001
Novo Nordisk70$951
Pfizer56$855
Astellas Pharma US Inc49$742
GSK44$695
Gilead29$695
Boehringer Ingelheim39$551
Merck35$516
Lundbeck LLC17$438
Johnson & Johnson21$336
Teva Pharmaceuticals USA, Inc.18$269
Sanofi-aventis U.S. LLC13$249
Radius Health, Inc.10$218
Abbott10$217
Biohaven Pharmaceuticals, Inc.12$213
Takeda Pharmaceuticals U.S.A., Inc.11$180
Kowa Pharmaceuticals America, Inc.12$165
Exact Sciences9$160
Ironshore Pharmaceuticals Inc.9$154
Biohaven Pharmaceutical Holding Company Ltd.16$149
Sumitomo Pharma America, Inc.7$123
Otsuka America Pharmaceutical, Inc.6$119
Vanda Pharmaceuticals Inc.6$99
Corium, LLC3$95
Upsher-smith Laboratories LLC5$92
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC6$91
Jazz Pharmaceuticals Inc.4$91
Axsome Therapeutics, Inc.4$84
Esperion Therapeutics, Inc.5$84
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)4$83
Dexcom, Inc.2$76
Genentech USA, Inc.4$75
Almatica Pharma LLC3$75
Eisai Inc.5$73
Seqirus USA Inc4$60
Shire North American Group Inc4$60
Arbor Pharmaceuticals, Inc.3$50
Tactile Systems Technology Inc1$49
Sanofi Pasteur Inc.3$48
IBSA Pharma Inc.3$45
Scilex Pharmaceuticals Inc.2$42
Lumenis, Inc1$40
Idorsia Pharmaceuticals US Inc2$39
Corcept Therapeutics2$39
Bausch Health US, LLC2$38
Medtronic2$38
Nalpropion Pharmaceuticals LLC2$37
Amarin Pharma, Inc.2$35
Neurelis, Inc.2$35
Mylan Specialty L.p.2$33
Impel Pharmaceuticals Inc.2$31
E.r. Squibb & Sons, L.L.C.2$30
Novartis2$28
Bristol Myers Squibb1$24
Phathom Pharmaceuticals, Inc.2$24
Bayer1$20
Ironwood Pharmaceuticals, Inc1$19

How this compares

$15,704 in reported general payments places this provider in the 95th percentile of 214 general practice providers in Delaware.

See all general practice providers in Delaware

Medicare billing

Part B allowed, 2024
$204,001
Medicare patients
290
Services billed
3,987

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin70$85,582
OxycontinOxycodone Hcl38$51,070
FarxigaDapagliflozin Propanediol30$48,918
EliquisApixaban31$44,393
XareltoRivaroxaban28$43,079
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$40,217
TrulicityDulaglutide17$39,745
WegovySemaglutide22$28,189
OzempicSemaglutide12$20,519
GemtesaVibegron26$19,824
MounjaroTirzepatide19$18,010
ArexvyRsvpref3 Antigen/As01e/Pf54$16,909
Repatha SureclickEvolocumab11$12,831
Diazepam29$11,389
Emgality PenGalcanezumab-Gnlm14$9,401

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$551$85,58270 claims
GSKTrelegy Ellipta, Arexvy, Anoro Ellipta, Shingrix, Breo Ellipta$695$79,298151 claims
Lilly USA, LLCTrulicity, Mounjaro$1,001$57,75536 claims
AstraZenecaFarxiga$1,202$48,91830 claims
Novo NordiskWegovy, Ozempic$951$48,70834 claims
PfizerEliquis, Paxlovid$855$45,82242 claims
Johnson & JohnsonXarelto$336$43,07928 claims
Sumitomo Pharma America, Inc.Gemtesa$123$19,82426 claims
AbbVieSynthroid$1,993$4,57886 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 214 general practice providers in Delaware.

Other general practice in Wilmington

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →